Stockreport

23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

23andMe Holding Co.  (ME) 
PDF 23ME-01473 (‘1473) seeks to restore anti-tumor immunity through NK and T cells by blocking the immunosuppressive effects of soluble ULBP6 ‘1473 also induces Fc receptor [Read more]